TNFRSF9 and neoplasm: The tumor-associated immune cell types (CD8+ and CD45RO+ T cells, CD20+ B cells, lymphocytes expressing the activation markers CD134, CD137, or PD-1, FOXP3+ regulatory T cells, NKp46+ NK cells, CD68+ macrophages, cells expressing CD16, myeloperoxidase+ neutrophil granulocytes (MPO)), DC-LAMP+ mature dendritic cells were identified in the analyzed samples.